Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (4255)	5/7/1998 12:28:00 AM
From: John Metcalf	Read Replies (1) \| Respond to of 6136

Rick, good point that contract manufacturing is not optimal. There are some additional considerations: 1) One should make allowance for expanded access programs and the runoff from them; viz; Agouron continues to make product available until reimbursement is available for each Expanded Access person, and until Viracept is approved in that person's country. 2) European reimbursement issues -- to the best of my knowledge, reimbursement is not yet decided in every country. 3) Startup costs -- includes shipping, warehousing, packaging, translation into various languages of package and marketing material, and cost of administration. Just a view from the trenches. The company has to hire and house the drivers, secretaries, etc. Someone has to buy the office furniture, someone has to be Regional Manager for South Niceplacetalive, and etc. Better margins will come.